{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-013481","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.841511+00:00","generated_at":"2026-06-12T03:37:36.747101+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Protalix reports Q2 net income of $19.3M on Elfabrio sales and $20M milestone","bullets":["Revenue from goods $15.1M (+344% YoY) driven by Elfabrio sales to Chiesi after FDA/EMA approvals.","License & R&D revenue $20.0M (+270% YoY) from $20M regulatory milestone payment from Chiesi.","Net income $19.3M ($0.29 basic EPS) vs net loss of $5.3M in Q2 2022; cash $48.2M.","Elfabrio received US FDA (May 10) and EU (May 5) approval for adult Fabry disease; launched in US by Chiesi.","PRX-115 phase I trial for severe gout ongoing; 16 patients dosed to date."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-013481","json":"https://secwatch.observer/filing/0001558370-23-013481.json","markdown":"https://secwatch.observer/filing/0001558370-23-013481.md","text":"https://secwatch.observer/filing/0001558370-23-013481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023013481/0001558370-23-013481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023013481/plx-20230807x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:37:36.747101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44728d0af329376c96adf9fc2928f6e00b574d1e","claim":"Protalix BioTherapeutics, Inc. reported financial results for three months ended June 30, 2023.","evidence_excerpt":"On August 7, 2023, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023013481/0001558370-23-013481-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}